Skip to Content

Generic Symlin Availability

Symlin is a brand name of pramlintide, approved by the FDA in the following formulation(s):

SYMLIN (pramlintide acetate - injectable;subcutaneous)

  • Manufacturer: ASTRAZENECA AB
    Approval date: March 16, 2005
    Strength(s): EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)
  • Manufacturer: ASTRAZENECA AB
    Approval date: September 25, 2007
    Strength(s): EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML), EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) [RLD]

Has a generic version of Symlin been approved?

No. There is currently no therapeutically equivalent version of Symlin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symlin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Amylin agonist peptides and uses therefor
    Patent 5,686,411
    Issued: November 11, 1997
    Inventor(s): Gaeta; Laura S. L. & Jones; Howard & Albrecht; Elisabeth
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
    Patent expiration dates:
    • March 16, 2019
      ✓ 
      Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods for regulating gastrointestinal motility
    Patent 6,114,304
    Issued: September 5, 2000
    Inventor(s): Kolterman; Orville G. & Young; Andrew A. & Rink; Timothy J. & Brown; Kathleen Ann Keiting
    Assignee(s): Amylin Pharmaceuticals, Inc.
    Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
    Patent expiration dates:
    • September 5, 2017
      ✓ 
      Patent use: USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
    • September 5, 2017
      ✓ 
      Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide